Therefore, it is critical to elucidate the relationship between the CDK4/6–cyclin D1 complex and the tumor microenvironment components after CDK4/6i treatment, namely, how these inhibitors induce favorable immunotherapeutic effects, or the reverse, in patients. The gene discussed is CDK4; the disease is neoplasm.